NCT06952803 2026-04-21
EvoPAR-PR02
AstraZeneca
Phase 3 Recruiting
Clinical Trials
14 trialsNCT06592924 2026-04-14
TRIPLE-SWITCH
Canadian Cancer Trials Group
Phase 3 Recruiting
NCT06691984 2026-03-06
Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)
Amgen
Phase 3 Recruiting
NCT06855277 2026-02-24
AcTFirst
Novartis
Phase 3 Recruiting
NCT06764485 2026-01-28
rechARge
Celgene
Phase 3 Recruiting
NCT04647526 2026-01-13
SPLASH
Eli Lilly and Company
Phase 3 Active not recruiting
NCT04446117 2025-12-18
CONTACT-02
Exelixis
Phase 3 Active not recruiting
NCT03678025 2025-09-11
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
SWOG Cancer Research Network
Phase 3 Recruiting
NCT05204927 2025-07-31
177Lu-PSMA-I&T for Metastatic Castration-Resistant Prostate Cancer
Curium US LLC
Phase 3 Active not recruiting
NCT06520345 2025-07-10
The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)
Telix Pharmaceuticals (Innovations) Pty Limited
Phase 3 Recruiting
NCT05288166 2025-06-27
CYCLONE 3
Eli Lilly and Company
Phase 3 Active not recruiting
NCT03072238 2025-06-06
IPATential150
Hoffmann-La Roche
Phase 3 Completed
NCT02043678 2025-02-19
ERA 223
Bayer
Phase 3 Completed
NCT01949337 2023-09-28
Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer
Alliance for Clinical Trials in Oncology
Phase 3 Unknown